The phase III European and Canadian psoriasis trial will be performed at thirty-six clinical centers in Canada, Germany, and Poland involving a total of 500 patients with moderate to severe psoriasis. The study will compare the effects of ISA247 with cyclosporine, a drug widely used to reduce the risk of organ rejection in transplant patients and already indicated for psoriasis.
To determine successful completion of the trial, the following parameters will be measured; Static Physician’s Global Assessment scores, Psoriasis Area and Severity Index scores and kidney function.
“Enrolling our first patient prior to year-end should facilitate us achieving our psoriasis development timelines,” stated Dr Randall Yatscoff, Isotechnika’s president & CEO. “We are confident that ISA247 will continue to demonstrate a strong safety and efficacy profile when directly compared to cyclosporine.”